| Editor's Note: Fierce Biotech will be taking a break for the Presidents Day holiday. Enjoy your long weekend, and we'll be back in your inboxes on Tuesday, February 20. |
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign up today! .png)
|
|
Today’s Big NewsFeb 16, 2024 |
| By Nick Paul Taylor The dominoes keep falling at Gilead. One week after reporting deaths in blood cancer patients, the Big Biotech has paused enrollment of magrolimab solid tumor trials after the FDA requested a partial clinical hold on the anti-CD47 monoclonal antibody. |
|
|
|
By Max Bayer Astellas is betting up to $800 million on Kelonia's in vivo genetic delivery tech through its cell therapy subsidiary Xyphos. Kelonia will earn $40 million in an upfront payment for the first candidate from the deal. |
By James Waldron Inventiva has paused enrolling new patients into a phase 3 trial of its lead liver disease drug after one participant experienced raised enzyme levels. |
Sponsored by Questex Fierce Life Sciences and Healthcare sit down with biotech, pharma, and healthcare executives at Fierce JPM Week. |
By Gabrielle Masson A Karuna Therapeutics stockholder is suing the biotech, claiming that the company and its directors didn’t include or misrepresented key information in a proxy statement urging shareholders to vote in favor of the proposed Bristol Myers Squibb merger. |
By Helen Floersh A new synthetic antibiotic appears to be effective against deadly drug-resistant pathogens, a development in the scramble to find solutions for the growing problem of antimicrobial resistance. |
By Helen Floersh The transplanted islet cells controlled the animal's glucose levels for six months without requiring insulin or immunosuppression, a step toward treating Type 1 diabetes without injectable insulin. |
By Ayla Ellison,Max Bayer This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics. |
By Max Bayer,Gabrielle Masson Exscientia fired founder and CEO Andrew Hopkins after an internal investigation found that he had “inappropriate” relationships with two other employees. Chief Scientific Officer Dave Hallett has been tapped as interim CEO while a full search gets underway. |
By Ben Adams The Sosei Group is making a major change to its corporate business as it renames and changes up its head office location. |
By Fraiser Kansteiner After picking up European rights to a pair of Eli Lilly migraine meds in December, Organon is hungry to ink more deals. |
By Angus Liu Takeda won FDA approval for Eohilia after a rejection in 2021. A group of U.S. lawmakers are seeking federal sanctions against WuXi AppTec and WuXi Biologics. LianBio, a prominent player in bringing foreign meds to China, will wind down. Plus more. |
By Anastassia Gliadkovskaya Nema is now in-network for commercial members with Horizon Blue Cross Blue Shield of New Jersey. Through this and another contract with a major national payer, Nema will reach about 3.6 million lives in the state. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics. |
|
|---|
|
|
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now! 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
